An Israeli and an Italian biopharmaceutical company have signed a memorandum of understanding with Israel's Health Ministry to supply an experimental plasma-derived treatment for the COVID-19 virus.
Kediron Biopharma of Italy has partnered with Israel's Kamada Ltd. to develop the new treatment, which is derived from plasma taken from patients who have recovered from COVID-19.
Follow Israel Hayom on Facebook and Twitter
Kamada will be in charge of the manufacturing. The Health Ministry has ordered enough to treat some 500 hospitalized COVID-19 patients.
"We are pleased to work in collaboration with Kamada on the development and global distribution of this important therapy, which we hope will help patients in Israel and around the world," said Kediron ChairmanPaolo Marcucci.
Kedrion and Kamada began collaborating on the potential plasma-based treatment in April of this year.
Kediron CEO Val Romberg said the news from Israel was "a welcome milestone" and added: "The progress made in Israel is a positive and encouraging sign for patients everywhere."
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
